Standard BioTools swaps Multiplex Bio sale for $5.5M Element deal, boosting Treeline merger cash by ~$15M

The Company terminated its prior agreement to sell the mass cytometry business to Multiplex Bio after its board determined it had received a superior proposal from GMT Venture Partners. The Company agreed to pay Multiplex Bio a $1.5 million termination fee.

GMT Venture will pay $1.0 million of the $1.5 million termination fee owed to Multiplex Bio on the Company's behalf, reducing the Company's out-of-pocket cost for terminating the prior agreement.

If the Element Purchase Agreement is terminated under specified circumstances, the Company must pay Element a $1.0 million termination fee and may also have to refund the $1.0 million Multiplex Termination Fee Contribution. The Company may also have to reimburse Element's expenses up to $125,000 if the deal is not completed by December 31, 2026, and up to an additional $125,000 if not completed by March 31, 2027.

The sale to Element cannot close until the Company's stockholders approve the transaction and the Company's pending merger with Treeline Biosciences is consummated. The agreement also includes a June 30, 2027 outside date, subject to up to two automatic three-month extensions.

The company disclosed under Item 1.02 that it terminated the Multiplex Bio Purchase Agreement, which was previously described in its Form 8-K filed on July 28, 2026, as amended on July 29, 2026. The filing incorporates the material terms of that agreement by reference to Exhibit 2.1 of the earlier 8-K.

The company announced two transactions: a sale of a business and a merger. The press release is furnished as Exhibit 99.1, but the 8-K body does not provide financial terms or counterparty details. Investors should read the exhibit for specifics.

Both the business disposition and the merger require stockholder approval. The company has filed a registration statement on Form S-4 and will amend its preliminary proxy statement to include the proposed sale. This means the transactions are not yet complete and remain subject to shareholder votes.

The company discloses that if either the sale of the business or the merger is terminated under certain circumstances, it may be required to pay a termination fee or other expenses. This is a standard risk factor but signals potential financial exposure if the deals fall through.

The company flags a risk that it could fail to maintain its Nasdaq listing. This is a forward-looking risk factor, not a current delisting notice, but it highlights uncertainty about the company's continued exchange listing.

The company acknowledges the possibility of stockholder litigation related to the sale or merger, which could lead to significant defense costs, indemnification, and liability. This is a risk factor, not a disclosed lawsuit, but it is a common concern in M&A transactions.

The company terminated its prior agreement to sell the Mass Cytometry business to Multiplex Bio and simultaneously entered into a new definitive agreement with Element Biosystems, an acquisition vehicle formed by GMT Venture Partners. The new sale price is $5.5 million in cash at closing, subject to customary adjustments.

The Board determined the Element transaction was a superior proposal after receiving an unsolicited acquisition proposal from GMT Venture on August 29, 2026. The prior Multiplex Bio purchase agreement was mutually terminated before entering the new definitive agreement with Element.

The Element transaction is expected to close by the end of 2026, substantially concurrently with the Treeline transaction, subject to stockholder approval and customary closing conditions. The Treeline transaction is also expected to close by the end of 2026.